Pregabalin for Restless Legs: What Sleep Recordings Showed

When restless legs disrupt your sleep, describe both the urge to move and the time spent awake. Bring a brief record of evening symptoms, awakenings and daytime difficulties to the prescribing review. The treatment discussion needs those details alongside any sleep-study report.

Who entered the crossover trial

The study randomized 85 adults with moderate-to-severe restless legs and substantial sleep disruption; 62 completed all three periods. Four-week periods compared pregabalin 300 mg/day, pramipexole 0.5 mg/day and placebo, with tapering and washout between periods. Pfizer sponsored the trial; authors disclosed industry ties.¹

This was not a general insomnia trial. Ask whether the explanation for your own disturbed sleep has been established before discussing a prescription change.

What the recordings showed

After four weeks, the estimated pregabalin-minus-placebo difference in wakefulness after sleep onset was −27.1 minutes (95% CI −35.8 to −18.4). This was the prespecified primary comparison. The awake-time comparison with pramipexole was descriptive, outside the protected significance-testing sequence.¹

Pramipexole produced the larger reduction in total sleeping leg movements, while pregabalin showed greater numerical improvement in sleep maintenance. Dizziness and sleepiness were common during pregabalin treatment. Short treatment periods cannot establish long-term safety or augmentation risk.¹

For your appointment, keep the questions separate: are you lying awake with an urge to move, being told that you kick while asleep, or waking for another reason? Record what you know directly and what someone else observed. Ask which problem the planned treatment is intended to improve.

Put the result into a current prescribing review

The 2025 AASM guideline strongly recommends pregabalin for adult restless legs, with moderate-certainty evidence. It conditionally suggests against standard pramipexole use because of long-term augmentation concerns, while allowing for individual short-term treatment preferences. This does not mean abruptly stopping an existing dopamine medicine; the guideline warns about severe rebound and calls for a clinician-led plan.²

The guideline also emphasizes iron studies and addressing aggravating factors, including untreated obstructive sleep apnea and medicines that worsen symptoms. Ask how those checks fit your situation before treating a medicine comparison as the whole assessment.²

In the US, treating restless legs with Lyrica is off-label. The current label warns about dizziness and sleepiness that can impair driving, and serious breathing suppression, particularly with opioids or other sedatives or underlying respiratory impairment. Tell the prescriber about breathing conditions and every sedating medicine.³

Kidney function affects dosing. The label requires gradual withdrawal over at least a week rather than abrupt stopping, and warns about suicidal thoughts or behavior, including reports after discontinuation. Request individual dose and stopping instructions; the trial’s dose is not a starting prescription.³

Did I Do That in My Sleep? distinguishes the awake urge of restless legs from observed sleeping kicks in “The Legs That Won’t Settle” and discusses the changed treatment advice.